摘要
采用免疫组化方法（ＬＳＡＢ法）对５８例膀胱癌和６例非癌膀胱粘膜标本进行ｒａｓＰ２１及ｐ５３蛋白产物检测。结果：５８例膀胱癌标本中３７例Ｐ２１检测阳性（６３．８％），３３例Ｐ５３检测阳性（５６．９％），对照组６例膀胱粘膜均未见阳性着色。Ｐ２１阳性率在Ⅰ、Ⅱ和Ⅲ级肿瘤中分别为２８．６％、４６．７％和７７．８％，在Ｔｉｓ～Ｔ１期和Ｔ２～Ｔ４期肿瘤中分别为４５．０％和７３．７％。Ｐ５３阳性率在Ⅰ、Ⅱ和Ⅲ级肿瘤中分别为１４．３％、４０．０％和７２．２％，在Ｔｉｓ～Ｔ１期和Ｔ２～Ｔ４期肿瘤中分别为３０．０％和７１．１％，显示Ｐ２１和Ｐ５３表达阳性率均随着膀胱癌病理分级、临床分期上升而升高，表达强度也随之增强。Ｐ２１和Ｐ５３阳性者的复发率和死亡率均明显高于阴性表达者。认为Ｐ２１和Ｐ５３可作为膀胱癌的生物学瘤标。
Protein products of ras P21 and P53 were detected by immunohistochemical method(LSAB method)in 58 specimens of transitional cell bladder carcinoma and in 6 normal bladder mucosa as controls.Ras P21 was positive in 37 of 58(63.8%)and P53 being positive in 33(56.9%)while both were negative in all the 6 controls.The P21 positive rate in gradeⅠ,ⅡandⅢturmors was 28.6%,46.7% and 77.8%,respectively and in stage Tis～T1 and T2～4 tumors being45.0%and 73.7%,The P53 positive rate in gradeⅠ,ⅡandⅢtumors was 14.3%,40.0%and 72.2 % respectively and in stage Tis-T1 and T2-4 tumors being 30.0%and 71.1%.The P21 and P53 positive rates and their level were significantly higher in poorly differentiated and invasive bladder cancer.The recurrence and death rates were higher than those of negative cases.It was concluded that P21 and P53 could be used as tumor markers for bladder cancer.
出处
《中华泌尿外科杂志》
CAS
CSCD
北大核心
1996年第1期20-23,共4页
Chinese Journal of Urology
